Fig. 1
From: The anti-inflammatory Annexin A1 induces the clearance and degradation of the amyloid-β peptide
ANXA1 is increased in postmortem brains of AD patients and in 5XFAD mice. a Representative blots and quantification of ANXA1 expression in the frontal cortex of neurologically healthy controls and sporadic Alzheimer’s patients and normalised to β-actin (n = 20 controls, 12 males, 8 females, range 40–97 years, mean age 73.24 ± 4 years, n = 22 AD cases, 11 males, 11 females, range 42–98 years, mean age 79.09 ± 3 years). b Representative blots and quantification of ANXA1 expression in the cortex of 5XFAD mice and wild-type littermates and normalised to β-actin (n = 6/group, males aged 12 and 26 weeks). c–e Representative images of human postmortem AD brain hippocampal sections stained for ANXA1. Arrows indicate expression in neurons (c), microglia (d) and astrocytic (e) staining. Values shown in graphs represent the mean value ± SEM and are expressed as fold change in comparison to the normalized control. Statistical analysis included Student’s independent two-tailed t test, *p < 0.05